BioSpace News Archive

CinPhloro Pharma, a CinRx Portfolio Company, Dosed First Participant in Phase 2 enviva Study of CIN-103 for Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).

Tenon Medical, Inc. announced that on February 15, 2024, the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application Serial Number 18/107,536 for Tenon’s Catamaran® SI Joint implant for stabilizing a dysfunctional sacroiliac joint.

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”) today announced that enrollment is now complete in its Phase 2 THIO-101 go-to-market clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC).

AtomVie Global Radiopharma Inc. (AtomVie), a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced strategic collaborations

Waters Corporation announced that Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Monday, March 4th, 2024 at 11:10AM Eastern Time

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported fourth quarter and full year 2023 financial results and corporate highlights.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming TD Cowen 44th Annual Healthcare Conference in Boston, MA.

Standard BioTools Inc. announced that management will participate in the following investor conferences:

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”) today announced it will report financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Thursday, March 7, 2024.

Frontier Medicines Corporation announced the close of an oversubscribed $80 million Series C financing.